Drugmakers Cipla and Solar Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Firm Restricted, respectively, for ‘Vonoprazan’ for India. The drug is used to deal with acid-related diseases amongst sufferers.
Cipla and Solar Pharma will independently commercialise the drug in India below their respective trademark manufacturers. Earlier this month, Torrent Pharma had additionally inked an analogous settlement on the identical drug.
Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the remedy of Gastroesophageal Reflux Illness (GERD). Vonoprozan can also be utilized in treating problems comparable to erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication, a word from Cipla stated.
- Additionally learn: Solar Pharma and Takeda signal settlement to introduce Voltapraz in India
#Cipla #Solar #Pharma #ink #nonexclusive #settlement #Takeda #acidreflux #drug